Spots Global Cancer Trial Database for essential thrombocythemia
Every month we try and update this database with for essential thrombocythemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | NCT00052520 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... B-cell Adult Ac... B-cell Childhoo... Childhood Chron... Childhood Myelo... Chronic Myelomo... Essential Throm... Polycythemia Ve... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... T-cell Adult Ac... T-cell Childhoo... | therapeutic all... aldesleukin peripheral bloo... allogeneic bone... laboratory biom... gene expression... immunologic tec... flow cytometry polymerase chai... cytogenetic ana... staining method | - | Fred Hutchinson Cancer Center | |
| Myeloproliferative Neoplasms: an In-depth Case-control Study | NCT01831635 | Polycythemia Ve... Essential Throm... Primary Myelofi... | Methodological ... Methodological ... Methodological ... | 18 Years - | Queen's University, Belfast | |
| Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms | NCT02823184 | Polycythemia Ve... Essential Throm... | RNA sample of t... | 18 Years - | University Hospital, Bordeaux | |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | NCT00445744 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child... | cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema... | - 65 Years | Fred Hutchinson Cancer Center | |
| Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients | NCT02893410 | Polycythemia Ve... Essential Throm... | 18 Years - | University Hospital, Brest | ||
| Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) | NCT04942080 | Myeloproliferat... Essential Throm... Primary Myelofi... Primary Myelofi... | CALR allele bur... | 18 Years - | University Hospital, Angers | |
| Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia | NCT01998828 | Polycythemia Ve... Essential Throm... | Momelotinib | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | NCT02055781 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Best Available ... | 18 Years - | CTI BioPharma | |
| Anagrelide Retard in Essential Thrombocythemia | NCT02076815 | Essential Throm... | Anagrelide reta... Thromboreductin | 18 Years - | AOP Orphan Pharmaceuticals AG | |
| Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance | NCT04285086 | Essential Throm... | Ropeginterferon... Anagrelide | 18 Years - | PharmaEssentia | |
| Familial Myeloproliferative Disorders | NCT00666289 | Polycythemia Ve... Essential Throm... Idiopathic Myel... | 7 Years - | Icahn School of Medicine at Mount Sinai | ||
| Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia | NCT02407080 | Polycythemia Ve... Essential Throm... | RG7388 Pegasys | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome | NCT00475020 | Myelofibrosis | Busulfan Fludarabine Thymoglobulin (... | - 75 Years | M.D. Anderson Cancer Center | |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis | NCT00132015 | Chronic Myelopr... Leukemia Lymphoma Nonneoplastic C... Precancerous Co... | tanespimycin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Correlative Biomarker Study in Patients With Myeloproliferative Disorders | NCT00665067 | Myeloproliferat... Myelofibrosis Idiopathic Myel... Essential Throm... Polycythemia Ve... | 18 Years - | Icahn School of Medicine at Mount Sinai | ||
| Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | NCT05031897 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myelomo... Essential Throm... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloid Leukemi... Myeloid Neoplas... Non-Hodgkin Lym... Plasma Cell Mye... Polycythemia Ve... Small Lymphocyt... | Hematopoietic C... Mycophenolate M... Tacrolimus Cyclophosphamid... Total-Body Irra... Donor Lymphocyt... Fludarabine Melphalan | 18 Years - | Thomas Jefferson University | |
| Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders | NCT00588991 | Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Chronic Myeloid... Chronic Myelomo... de Novo Myelody... Essential Throm... Hematopoietic a... Myelodysplastic... Polycythemia Ve... Recurrent Adult... Recurrent Adult... Secondary Myelo... | Carboplatin Laboratory Biom... Topotecan Hydro... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Correlative Biomarker Study in Patients With Myeloproliferative Disorders | NCT00665067 | Myeloproliferat... Myelofibrosis Idiopathic Myel... Essential Throm... Polycythemia Ve... | 18 Years - | Icahn School of Medicine at Mount Sinai | ||
| CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia | NCT03972943 | CALR Gene Mutat... Essential Throm... JAK2 Gene Mutat... MPL Gene Mutati... Obstructive Sle... Polycythemia Ve... | Continuous Posi... Patient Observa... Questionnaire A... | 30 Years - 85 Years | University of Utah | |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | NCT00445744 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child... | cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema... | - 65 Years | Fred Hutchinson Cancer Center | |
| CC-4047 in Treating Patients With Myelofibrosis | NCT00669578 | Chronic Myelopr... Secondary Myelo... | CC-4047 | 18 Years - 120 Years | Mayo Clinic | |
| Myeloproliferative Neoplastic Diseases Observatory From Brest | NCT02897297 | Polycythemia Ve... Essential Throm... Primary Myelofi... | - | University Hospital, Brest | ||
| Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation | NCT02311569 | Myeloproliferat... Primary Myelofi... Essential Throm... Polycythemia Ve... | Mirabegron | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients | NCT01970930 | Polycythemia Ve... Essential Throm... | Blood specimen | - | Icahn School of Medicine at Mount Sinai | |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | NCT05936359 | Myeloproliferat... | INCA033989 Ruxolitinib | 18 Years - | Incyte Corporation | |
| The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase | NCT03907436 | Myeloproliferat... Myeloproliferat... Myelofibrosis Polycythemia Ve... Essential Throm... | USDA Diet Mediterranean D... | 18 Years - | University of California, Irvine | |
| Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer | NCT00296023 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo... | 18 Years - 75 Years | University of California, San Francisco | |
| Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance | NCT04285086 | Essential Throm... | Ropeginterferon... Anagrelide | 18 Years - | PharmaEssentia | |
| Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | NCT01014546 | Essential Throm... Polycythemia Ve... Primary Myelofi... | Arsenic Trioxid... Ascorbic Acid Laboratory Biom... Pharmacological... | 19 Years - | Roswell Park Cancer Institute | |
| Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms | NCT01520220 | Myeloproliferat... Polycythemia Ve... Essential Throm... Myelofibrosis | LY2784544 | 18 Years - | Eli Lilly and Company | |
| Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera | NCT01243073 | Essential Throm... Polycythemia Ve... | Imetelstat | 18 Years - | Geron Corporation | |
| Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes | NCT06361641 | Myeloproliferat... Polycythemia Ve... Essential Throm... Primary Myelofi... | Monocytes signa... | 18 Years - | University Hospital, Angers | |
| Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) | NCT02953704 | MPN (Myeloproli... | 18 Years - | Incyte Corporation | ||
| Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) | NCT02410551 | Myeloproliferat... | Pacritinib Busulfan Questionnaires Phone Calls Allogeneic Stem... Fludarabine | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Research Tissue Bank | NCT00666549 | Myelofibrosis Idiopathic Myel... Essential Throm... Polycythemia Ve... | 18 Years - | Icahn School of Medicine at Mount Sinai | ||
| Imatinib Mesylate in Treating Patients With Myelofibrosis | NCT00039416 | Chronic Myelomo... Essential Throm... Polycythemia Ve... Primary Myelofi... | imatinib mesyla... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | NCT01014546 | Essential Throm... Polycythemia Ve... Primary Myelofi... | Arsenic Trioxid... Ascorbic Acid Laboratory Biom... Pharmacological... | 19 Years - | Roswell Park Cancer Institute | |
| Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | NCT01014546 | Essential Throm... Polycythemia Ve... Primary Myelofi... | Arsenic Trioxid... Ascorbic Acid Laboratory Biom... Pharmacological... | 19 Years - | Roswell Park Cancer Institute | |
| Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders | NCT00397813 | Atypical Chroni... Chronic Myelomo... de Novo Myelody... Essential Throm... Myeloproliferat... Paroxysmal Noct... Polycythemia Ve... Polycythemia Ve... Primary Myelofi... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto... | Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Total-Body Irra... | 50 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Tipifarnib in Treating Patients With Advanced Hematologic Cancer | NCT00005967 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) | NCT01259856 | High Risk Polyc... High Risk Essen... | PEGASYS Hydroxyurea Aspirin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Myeloproliferative Neoplastic Diseases Observatory From Brest | NCT02897297 | Polycythemia Ve... Essential Throm... Primary Myelofi... | - | University Hospital, Brest | ||
| A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | NCT01787552 | Primary Myelofi... Thrombocytosis Essential Throm... Polycythemia Ve... Myeloproliferat... Bone Marrow Dis... Hematologic Dis... Blood Coagulati... Blood Platelet ... Hemorrhagic Dis... | LDE225 INC424 | 18 Years - | Novartis | |
| Ruxolitinib in Thrombocythemia and Polycythemia Vera | NCT04644211 | Essential Throm... Polycythemia Ve... | Ruxolitinib | 18 Years - | Massachusetts General Hospital | |
| A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis | NCT00745550 | Myelofibrosis Myeloproliferat... Polycythemia Ve... Essential Throm... | SB1518 | 18 Years - | S*BIO | |
| Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) | NCT01167166 | Acute Myelocyti... Acute Lymphocyt... Myeloproliferat... Chronic Myeloid... | rigosertib | 18 Years - | Traws Pharma, Inc. | |
| Imatinib Mesylate in Treating Patients With Myelofibrosis | NCT00039416 | Chronic Myelomo... Essential Throm... Polycythemia Ve... Primary Myelofi... | imatinib mesyla... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms | NCT03566446 | Myeloproliferat... Essential Throm... Myelofibrosis | CALRLong36 pept... | 18 Years - | Herlev Hospital | |
| Myeloproliferative Neoplasms (MPNs) Patient Registry | NCT02760238 | Primary Myelofi... Polycythemia Ve... Essential Throm... Mastocytosis Leukemia, Myelo... Leukemia, Myelo... Chronic Eosinop... Myelodysplastic... Neoplasms Leukemia, Myelo... | Observational | - | University Health Network, Toronto | |
| Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | NCT03878199 | Essential Throm... Myelofibrosis Myeloproliferat... Polycythemia Ve... Secondary Acute... | Allogeneic Hema... Liposome-encaps... Ruxolitinib | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders | NCT00433862 | Polycythemia Ve... Essential Throm... Idiopathic Myel... Neutrophils Chronic Myelopr... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) | NCT01259817 | High Risk Polyc... High Risk Essen... | PEGASYS Aspirin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms | NCT06150157 | Myeloproliferat... Essential Throm... Neoplasms Myelofibrosis | JNJ-88549968 | 18 Years - | Janssen Research & Development, LLC | |
| Myeloproliferative Neoplasms (MPNs) Patient Registry | NCT02760238 | Primary Myelofi... Polycythemia Ve... Essential Throm... Mastocytosis Leukemia, Myelo... Leukemia, Myelo... Chronic Eosinop... Myelodysplastic... Neoplasms Leukemia, Myelo... | Observational | - | University Health Network, Toronto | |
| Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) | NCT02953704 | MPN (Myeloproli... | 18 Years - | Incyte Corporation | ||
| A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET | NCT05482971 | Essential Throm... | Ropeginterferon... | 18 Years - | PharmaEssentia | |
| Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation | NCT02311569 | Myeloproliferat... Primary Myelofi... Essential Throm... Polycythemia Ve... | Mirabegron | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML | NCT00069992 | Chronic Myelopr... Leukemia Myelodysplastic... | Total Body Irra... Fludarabine Campath 1H | - | Baylor College of Medicine | |
| Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes | NCT00715247 | Polycythemia Ve... Essential Throm... Myelofibrosis | - | University of Utah | ||
| Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders | NCT00397813 | Atypical Chroni... Chronic Myelomo... de Novo Myelody... Essential Throm... Myeloproliferat... Paroxysmal Noct... Polycythemia Ve... Polycythemia Ve... Primary Myelofi... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto... | Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Total-Body Irra... | 50 Years - 75 Years | Fred Hutchinson Cancer Center | |
| The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase | NCT03907436 | Myeloproliferat... Myeloproliferat... Myelofibrosis Polycythemia Ve... Essential Throm... | USDA Diet Mediterranean D... | 18 Years - | University of California, Irvine | |
| Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study) | NCT03745378 | Polycythemia Ve... Essential Throm... Myelofibrosis | JAK2V617F mutat... | - | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | |
| Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia | NCT02407080 | Polycythemia Ve... Essential Throm... | RG7388 Pegasys | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Familial Myeloproliferative Disorders | NCT00666289 | Polycythemia Ve... Essential Throm... Idiopathic Myel... | 7 Years - | Icahn School of Medicine at Mount Sinai | ||
| Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders | NCT00433862 | Polycythemia Ve... Essential Throm... Idiopathic Myel... Neutrophils Chronic Myelopr... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia | NCT03972943 | CALR Gene Mutat... Essential Throm... JAK2 Gene Mutat... MPL Gene Mutati... Obstructive Sle... Polycythemia Ve... | Continuous Posi... Patient Observa... Questionnaire A... | 30 Years - 85 Years | University of Utah | |
| A Study of GLB-001 in Patients With Myeloid Malignancies | NCT06378437 | Polycythemia Ve... Essential Throm... Myelofibrosis Myelodysplastic... Acute Myeloid L... Myeloid Maligna... | GLB-001 | 18 Years - | Hangzhou GluBio Pharmaceutical Co., Ltd. | |
| Asian Myeloproliferative Neoplasm (MPN) Registry | NCT05882773 | Myeloproliferat... Polycythemia Ve... Essential Throm... Post-polycythem... Post-essential ... Primary Myelofi... Primary Myelofi... Primary Myelofi... | 18 Years - | The University of Hong Kong | ||
| Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia | NCT00718159 | Acute Myeloid L... Essential Throm... | LY573636-sodium | 18 Years - | Eli Lilly and Company | |
| A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera | NCT01901432 | Polycythemia Ve... | Givinostat | 18 Years - | Italfarmaco | |
| CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms | NCT03566446 | Myeloproliferat... Essential Throm... Myelofibrosis | CALRLong36 pept... | 18 Years - | Herlev Hospital | |
| Dual Vaccine Trial in Myeloproliferative Neoplasms | NCT04051307 | Polycythemia Ve... Essential Throm... | PD-L1 peptide: ... Arginase1 pepti... | 18 Years - | Herlev Hospital | |
| Study of Select Combinations in Adults With Myelofibrosis | NCT04283526 | Primary Myelofi... Myelofibrosis PMF Post-Essential ... Post-Polycythem... | MBG453 NIS793 Spartalizumab Decitabine | 18 Years - | Novartis | |
| A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia | NCT00866762 | Polycythemia Ve... Essential Throm... | HDAC inhibitor ... | 18 Years - | Copenhagen University Hospital at Herlev | |
| A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV | NCT05481151 | Polycythemia Ve... | P1101 (Ropegint... Ropeginterferon... | 18 Years - | PharmaEssentia | |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | NCT02055781 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Best Available ... | 18 Years - | CTI BioPharma | |
| Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | NCT02556931 | Myelodysplastic... Chronic Myelomo... Small Lymphocyt... Chronic Lymphoc... Prolymphocytic ... Chronic Myeloid... Chronic Myelopr... Multiple Myelom... Plasma Cell Neo... Plasma Cell Dys... Myelofibrosis Polycythemia Ve... Essential Throm... Plasma Cell Leu... | Fludarabine Cyclophosphamid... Total body irra... Tacrolimus Mycophenolate m... | - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Myeloproliferative Neoplasms (MPNs) Patient Registry | NCT02760238 | Primary Myelofi... Polycythemia Ve... Essential Throm... Mastocytosis Leukemia, Myelo... Leukemia, Myelo... Chronic Eosinop... Myelodysplastic... Neoplasms Leukemia, Myelo... | Observational | - | University Health Network, Toronto | |
| Myeloproliferative Neoplasms: an In-depth Case-control Study | NCT01831635 | Polycythemia Ve... Essential Throm... Primary Myelofi... | Methodological ... Methodological ... Methodological ... | 18 Years - | Queen's University, Belfast |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
